Short-Term Frovatriptan for the Prevention of Difficult-To-Treat Menstrual Migraine Attacks
The efficacy of a 6-day regimen of frovatriptan for menstrual migraine (MM; attacks starting on day -2 to +3 of menses) prevention in women with difficult-to-treat MM was assessed. Women with a documented inadequate response to triptans for acute MM treatment were included in this placebo-controlled...
Gespeichert in:
| Veröffentlicht in: | Cephalalgia 2009-11, Vol.29 (11), p.1133-1148 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1148 |
|---|---|
| container_issue | 11 |
| container_start_page | 1133 |
| container_title | Cephalalgia |
| container_volume | 29 |
| creator | Brandes, JL Poole, AC Kallela, M Schreiber, CP MacGregor, EA Silberstein, SD Tobin, J Shaw, R |
| description | The efficacy of a 6-day regimen of frovatriptan for menstrual migraine (MM; attacks starting on day -2 to +3 of menses) prevention in women with difficult-to-treat MM was assessed. Women with a documented inadequate response to triptans for acute MM treatment were included in this placebo-controlled, parallel-group trial. Women were randomized to double-blind treatment for three perimenstrual periods (PMPs) with either frovatriptan 2.5 mg (q.d. or b.i.d.) or placebo initiated 2 days before anticipated MM. The efficacy analysis included 410 women with 85% completing three double-blind PMPs. The mean number of headache-free PMPs was 0.92 with frovatriptan b.i.d., 0.69 with frovatriptan q.d. and 0.42 with placebo [P < 0.001 (b.i.d.) and P < 0.02 (q.d.) vs. placebo]. When migraine occurred, severity was reduced with frovatriptan q.d. (P < 0.001) and b.i.d. (P < 0.001) vs. placebo. Both frovatriptan regimens were well tolerated. In women with difficult-to-treat MM, a 6-day regimen of frovatriptan significantly reduced MM incidence and severity. |
| doi_str_mv | 10.1111/j.1468-2982.2009.01840.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_AFRWT</sourceid><recordid>TN_cdi_proquest_miscellaneous_734076266</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1111_j.1468-2982.2009.01840.x</sage_id><sourcerecordid>734076266</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4960-33a701f478d6d552b3601d1ea0f1028e9703ba8781beb3f09b534fcc675bad8e3</originalsourceid><addsrcrecordid>eNqNkUFv1DAQhS0EokvhLyCf4JR0HCeOc0Gqti2t1IpKXU4cLCcZt16y8WI7pf33OOyqvUF9sSV_783oPUIog5ylc7TOWSlkVjSyyAuAJgcmS8gfXpHF08drsgDOecagKA_IuxDWAFAJEG_JAWskYxXwBflxc-d8zFboN_TMu3sdvd1GPVLjPI13SK893uMYrRupM_TEGmO7aUgKl6086kivcAzRT3qgV_bWazsiPY5Rdz_De_LG6CHgh_19SL6fna6W59nlt68Xy-PLrCsbARnnugZmylr2oq-qouUCWM9Qg0m7S2xq4K2WtWQtttxA01a8NF0n6qrVvUR-SD7vfLfe_ZowRLWxocNh0CO6Kaial1CLQohEfvonWTBWyKqsEyh3YOddCB6N2nq70f5RMVBzBWqt5qTVnLSaK1B_K1APSfpxP2NqN9g_C_eZJ-DLDvhtB3x8sbFanl6fz89kUO0Mgr5FtXaTH1O8_9_sDwzxpM4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>21128547</pqid></control><display><type>article</type><title>Short-Term Frovatriptan for the Prevention of Difficult-To-Treat Menstrual Migraine Attacks</title><source>Sage Journals GOLD Open Access 2024</source><creator>Brandes, JL ; Poole, AC ; Kallela, M ; Schreiber, CP ; MacGregor, EA ; Silberstein, SD ; Tobin, J ; Shaw, R</creator><creatorcontrib>Brandes, JL ; Poole, AC ; Kallela, M ; Schreiber, CP ; MacGregor, EA ; Silberstein, SD ; Tobin, J ; Shaw, R</creatorcontrib><description>The efficacy of a 6-day regimen of frovatriptan for menstrual migraine (MM; attacks starting on day -2 to +3 of menses) prevention in women with difficult-to-treat MM was assessed. Women with a documented inadequate response to triptans for acute MM treatment were included in this placebo-controlled, parallel-group trial. Women were randomized to double-blind treatment for three perimenstrual periods (PMPs) with either frovatriptan 2.5 mg (q.d. or b.i.d.) or placebo initiated 2 days before anticipated MM. The efficacy analysis included 410 women with 85% completing three double-blind PMPs. The mean number of headache-free PMPs was 0.92 with frovatriptan b.i.d., 0.69 with frovatriptan q.d. and 0.42 with placebo [P < 0.001 (b.i.d.) and P < 0.02 (q.d.) vs. placebo]. When migraine occurred, severity was reduced with frovatriptan q.d. (P < 0.001) and b.i.d. (P < 0.001) vs. placebo. Both frovatriptan regimens were well tolerated. In women with difficult-to-treat MM, a 6-day regimen of frovatriptan significantly reduced MM incidence and severity.</description><identifier>ISSN: 0333-1024</identifier><identifier>EISSN: 1468-2982</identifier><identifier>DOI: 10.1111/j.1468-2982.2009.01840.x</identifier><identifier>PMID: 19811503</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Adolescent ; Carbazoles - therapeutic use ; Double-Blind Method ; Female ; frovatriptan ; headache ; History, 16th Century ; Humans ; Menstrual migraine ; Menstruation ; Middle Aged ; migraine ; Migraine Disorders - etiology ; Migraine Disorders - prevention & control ; Serotonin Receptor Agonists - therapeutic use ; short‐term prevention ; Tryptamines - therapeutic use ; Young Adult</subject><ispartof>Cephalalgia, 2009-11, Vol.29 (11), p.1133-1148</ispartof><rights>2009 International Headache Society</rights><rights>Blackwell Publishing Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4960-33a701f478d6d552b3601d1ea0f1028e9703ba8781beb3f09b534fcc675bad8e3</citedby><cites>FETCH-LOGICAL-c4960-33a701f478d6d552b3601d1ea0f1028e9703ba8781beb3f09b534fcc675bad8e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1111/j.1468-2982.2009.01840.x$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1111/j.1468-2982.2009.01840.x$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,780,784,21819,21966,27853,27924,27925,43621,43622,44945,45333</link.rule.ids><linktorsrc>$$Uhttps://journals.sagepub.com/doi/full/10.1111/j.1468-2982.2009.01840.x?utm_source=summon&utm_medium=discovery-provider$$EView_record_in_SAGE_Publications$$FView_record_in_$$GSAGE_Publications</linktorsrc><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19811503$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Brandes, JL</creatorcontrib><creatorcontrib>Poole, AC</creatorcontrib><creatorcontrib>Kallela, M</creatorcontrib><creatorcontrib>Schreiber, CP</creatorcontrib><creatorcontrib>MacGregor, EA</creatorcontrib><creatorcontrib>Silberstein, SD</creatorcontrib><creatorcontrib>Tobin, J</creatorcontrib><creatorcontrib>Shaw, R</creatorcontrib><title>Short-Term Frovatriptan for the Prevention of Difficult-To-Treat Menstrual Migraine Attacks</title><title>Cephalalgia</title><addtitle>Cephalalgia</addtitle><description>The efficacy of a 6-day regimen of frovatriptan for menstrual migraine (MM; attacks starting on day -2 to +3 of menses) prevention in women with difficult-to-treat MM was assessed. Women with a documented inadequate response to triptans for acute MM treatment were included in this placebo-controlled, parallel-group trial. Women were randomized to double-blind treatment for three perimenstrual periods (PMPs) with either frovatriptan 2.5 mg (q.d. or b.i.d.) or placebo initiated 2 days before anticipated MM. The efficacy analysis included 410 women with 85% completing three double-blind PMPs. The mean number of headache-free PMPs was 0.92 with frovatriptan b.i.d., 0.69 with frovatriptan q.d. and 0.42 with placebo [P < 0.001 (b.i.d.) and P < 0.02 (q.d.) vs. placebo]. When migraine occurred, severity was reduced with frovatriptan q.d. (P < 0.001) and b.i.d. (P < 0.001) vs. placebo. Both frovatriptan regimens were well tolerated. In women with difficult-to-treat MM, a 6-day regimen of frovatriptan significantly reduced MM incidence and severity.</description><subject>Adolescent</subject><subject>Carbazoles - therapeutic use</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>frovatriptan</subject><subject>headache</subject><subject>History, 16th Century</subject><subject>Humans</subject><subject>Menstrual migraine</subject><subject>Menstruation</subject><subject>Middle Aged</subject><subject>migraine</subject><subject>Migraine Disorders - etiology</subject><subject>Migraine Disorders - prevention & control</subject><subject>Serotonin Receptor Agonists - therapeutic use</subject><subject>short‐term prevention</subject><subject>Tryptamines - therapeutic use</subject><subject>Young Adult</subject><issn>0333-1024</issn><issn>1468-2982</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkUFv1DAQhS0EokvhLyCf4JR0HCeOc0Gqti2t1IpKXU4cLCcZt16y8WI7pf33OOyqvUF9sSV_783oPUIog5ylc7TOWSlkVjSyyAuAJgcmS8gfXpHF08drsgDOecagKA_IuxDWAFAJEG_JAWskYxXwBflxc-d8zFboN_TMu3sdvd1GPVLjPI13SK893uMYrRupM_TEGmO7aUgKl6086kivcAzRT3qgV_bWazsiPY5Rdz_De_LG6CHgh_19SL6fna6W59nlt68Xy-PLrCsbARnnugZmylr2oq-qouUCWM9Qg0m7S2xq4K2WtWQtttxA01a8NF0n6qrVvUR-SD7vfLfe_ZowRLWxocNh0CO6Kaial1CLQohEfvonWTBWyKqsEyh3YOddCB6N2nq70f5RMVBzBWqt5qTVnLSaK1B_K1APSfpxP2NqN9g_C_eZJ-DLDvhtB3x8sbFanl6fz89kUO0Mgr5FtXaTH1O8_9_sDwzxpM4</recordid><startdate>200911</startdate><enddate>200911</enddate><creator>Brandes, JL</creator><creator>Poole, AC</creator><creator>Kallela, M</creator><creator>Schreiber, CP</creator><creator>MacGregor, EA</creator><creator>Silberstein, SD</creator><creator>Tobin, J</creator><creator>Shaw, R</creator><general>SAGE Publications</general><general>Blackwell Publishing Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7X8</scope></search><sort><creationdate>200911</creationdate><title>Short-Term Frovatriptan for the Prevention of Difficult-To-Treat Menstrual Migraine Attacks</title><author>Brandes, JL ; Poole, AC ; Kallela, M ; Schreiber, CP ; MacGregor, EA ; Silberstein, SD ; Tobin, J ; Shaw, R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4960-33a701f478d6d552b3601d1ea0f1028e9703ba8781beb3f09b534fcc675bad8e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Adolescent</topic><topic>Carbazoles - therapeutic use</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>frovatriptan</topic><topic>headache</topic><topic>History, 16th Century</topic><topic>Humans</topic><topic>Menstrual migraine</topic><topic>Menstruation</topic><topic>Middle Aged</topic><topic>migraine</topic><topic>Migraine Disorders - etiology</topic><topic>Migraine Disorders - prevention & control</topic><topic>Serotonin Receptor Agonists - therapeutic use</topic><topic>short‐term prevention</topic><topic>Tryptamines - therapeutic use</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Brandes, JL</creatorcontrib><creatorcontrib>Poole, AC</creatorcontrib><creatorcontrib>Kallela, M</creatorcontrib><creatorcontrib>Schreiber, CP</creatorcontrib><creatorcontrib>MacGregor, EA</creatorcontrib><creatorcontrib>Silberstein, SD</creatorcontrib><creatorcontrib>Tobin, J</creatorcontrib><creatorcontrib>Shaw, R</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Cephalalgia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Brandes, JL</au><au>Poole, AC</au><au>Kallela, M</au><au>Schreiber, CP</au><au>MacGregor, EA</au><au>Silberstein, SD</au><au>Tobin, J</au><au>Shaw, R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Short-Term Frovatriptan for the Prevention of Difficult-To-Treat Menstrual Migraine Attacks</atitle><jtitle>Cephalalgia</jtitle><addtitle>Cephalalgia</addtitle><date>2009-11</date><risdate>2009</risdate><volume>29</volume><issue>11</issue><spage>1133</spage><epage>1148</epage><pages>1133-1148</pages><issn>0333-1024</issn><eissn>1468-2982</eissn><abstract>The efficacy of a 6-day regimen of frovatriptan for menstrual migraine (MM; attacks starting on day -2 to +3 of menses) prevention in women with difficult-to-treat MM was assessed. Women with a documented inadequate response to triptans for acute MM treatment were included in this placebo-controlled, parallel-group trial. Women were randomized to double-blind treatment for three perimenstrual periods (PMPs) with either frovatriptan 2.5 mg (q.d. or b.i.d.) or placebo initiated 2 days before anticipated MM. The efficacy analysis included 410 women with 85% completing three double-blind PMPs. The mean number of headache-free PMPs was 0.92 with frovatriptan b.i.d., 0.69 with frovatriptan q.d. and 0.42 with placebo [P < 0.001 (b.i.d.) and P < 0.02 (q.d.) vs. placebo]. When migraine occurred, severity was reduced with frovatriptan q.d. (P < 0.001) and b.i.d. (P < 0.001) vs. placebo. Both frovatriptan regimens were well tolerated. In women with difficult-to-treat MM, a 6-day regimen of frovatriptan significantly reduced MM incidence and severity.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>19811503</pmid><doi>10.1111/j.1468-2982.2009.01840.x</doi><tpages>16</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | ISSN: 0333-1024 |
| ispartof | Cephalalgia, 2009-11, Vol.29 (11), p.1133-1148 |
| issn | 0333-1024 1468-2982 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_734076266 |
| source | Sage Journals GOLD Open Access 2024 |
| subjects | Adolescent Carbazoles - therapeutic use Double-Blind Method Female frovatriptan headache History, 16th Century Humans Menstrual migraine Menstruation Middle Aged migraine Migraine Disorders - etiology Migraine Disorders - prevention & control Serotonin Receptor Agonists - therapeutic use short‐term prevention Tryptamines - therapeutic use Young Adult |
| title | Short-Term Frovatriptan for the Prevention of Difficult-To-Treat Menstrual Migraine Attacks |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T22%3A36%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_AFRWT&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Short-Term%20Frovatriptan%20for%20the%20Prevention%20of%20Difficult-To-Treat%20Menstrual%20Migraine%20Attacks&rft.jtitle=Cephalalgia&rft.au=Brandes,%20JL&rft.date=2009-11&rft.volume=29&rft.issue=11&rft.spage=1133&rft.epage=1148&rft.pages=1133-1148&rft.issn=0333-1024&rft.eissn=1468-2982&rft_id=info:doi/10.1111/j.1468-2982.2009.01840.x&rft_dat=%3Cproquest_AFRWT%3E734076266%3C/proquest_AFRWT%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=21128547&rft_id=info:pmid/19811503&rft_sage_id=10.1111_j.1468-2982.2009.01840.x&rfr_iscdi=true |